The Company has been started in April 2005 together with the Fox Chase Cancer Center in Philadelphia by a scientific and business team that has worked on the discovery and development of novel cancer treatments in various biotech and pharma companies in their past.

NexusPharma is largely following a "virtual development company" concept, building on a network of scientific experts and advisors in cancer research and drug development to advance its first-in-class drug candidates into clinical development:

Research: The team is lead by Vladimir Khazak (CSO, chief scientific officer), supported by Erica Golemis and Michael F. Ochs (FCCC, Philadelphia), Channing J. Der and Sharon Campbell (UNC, Chapel Hill), Fuyuhiko Tamanoi (UCLA, Los Angeles), and David Tuveson (UPenn, Philadelphia).

Home | Contacts | Directions